This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Navtemadlin
DrugBank Accession Number
DB15299
Background

Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 568.55
Monoisotopic: 567.1612998
Chemical Formula
C28H35Cl2NO5S
Synonyms
Not Available
External IDs
  • AMG 232
  • AMG-232
  • KRT-232
  • MDM2 INHIBITOR AMG-232

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Phenylpiperidines / Chlorobenzenes / Delta lactams / Piperidinones / Aryl chlorides / Tertiary carboxylic acid amides / Sulfones / Monocarboxylic acids and derivatives / Azacyclic compounds / Carboxylic acids
show 6 more
Substituents
Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid derivative / Chlorobenzene
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
7R7G6EH5UL
CAS number
1352066-68-2
InChI Key
DRLCSJFKKILATL-YWCVFVGNSA-N
InChI
InChI=1S/C28H35Cl2NO5S/c1-17(2)24(16-37(35,36)18(3)4)31-26(19-9-11-21(29)12-10-19)23(20-7-6-8-22(30)13-20)14-28(5,27(31)34)15-25(32)33/h6-13,17-18,23-24,26H,14-16H2,1-5H3,(H,32,33)/t23-,24-,26-,28-/m1/s1
IUPAC Name
2-[(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2S)-3-methyl-1-(propane-2-sulfonyl)butan-2-yl]-2-oxopiperidin-3-yl]acetic acid
SMILES
CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)C1=CC=CC(Cl)=C1)C1=CC=C(Cl)C=C1

References

General References
Not Available
ChemSpider
31132728
BindingDB
50448947
ChEMBL
CHEMBL3125702
ZINC
ZINC000103248035

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentPolycythemia Vera (PV)1
2RecruitingTreatmentExtensive-stage Small Cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer (SCLC) / Small Cell Lung Cancer (SCLC)1
2RecruitingTreatmentPost-essential Thrombocythemia Myelofibrosis (Post-ET MF) / Post-polycythemia Vera Myelofibrosis (Post-PV MF) / Primary Myelofibrosis (PMF)1
2, 3RecruitingTreatmentPost-Essential Thrombocythemia MF (Post-ET-MF) / Post-Polycythemia Vera MF (Post-PV-MF) / Primary Myelofibrosis (PMF)1
1CompletedTreatmentAcute Myeloid Leukemia (AML) / Advanced Malignancies / Cancer / Oncology / Oncology Patients1
1CompletedTreatmentAdvanced Malignancies / Cancer / Glioblastoma Multiforme (GBM) / Multiple Myeloma (MM) / Oncology / Oncology Patients / Solid Tumors, Advanced Solid Tumors / Tumors1
1CompletedTreatmentAdvanced Malignancies / Cancer / Melanoma / Oncology / Oncology Patients / Solid Tumors, Advanced Solid Tumors / Tumors1
1RecruitingTreatmentAcute Myeloid Leukemia (AML) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome1
1RecruitingTreatmentPlasmacytoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1RecruitingTreatmentResectable Soft Tissue Sarcoma / Soft Tissue Sarcoma (STS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000274 mg/mLALOGPS
logP4.27ALOGPS
logP5.86ChemAxon
logS-6.3ALOGPS
pKa (Strongest Acidic)4.19ChemAxon
pKa (Strongest Basic)-0.0047ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area91.75 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity146.04 m3·mol-1ChemAxon
Polarizability58.35 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 15:09 / Updated at August 13, 2021 04:44